A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
Completed
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Georgia Cancer Specialists, Atlanta, Georgia
Conditions: HER-2 Gene Amplification
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
Terminated
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of esophageal cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: Augusta Oncology Associates - Walton Way, Augusta, Georgia +2 locations
Conditions: Esophageal Cancer
Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel, cisplatin, and filgrastim combined w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2015
Locations: Emory University Hospital - Atlanta, Atlanta, Georgia +3 locations
Conditions: Head and Neck Cancer
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy following surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients who have undergone surgery for stage III or stage IV head and neck cancer.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/14/2015
Locations: Emory University Hospital - Atlanta, Atlanta, Georgia +3 locations
Conditions: Head and Neck Cancer
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
Terminated
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemotherapy together with radiation therapy is more effective with or without vandetanib in treating patients with head... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2015
Locations: Winship Cancer Institute of Emory University, Altanta, Georgia
Conditions: Head and Neck Cancer
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: CCOP - Atlanta Regional, Atlanta, Georgia +1 locations
Conditions: Multiple Myeloma
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
Completed
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa is more effective with or without combination chemotherapy and interleukin-2 for melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Winship Cancer Institute of Emory University, Altanta, Georgia +2 locations
Conditions: Melanoma (Skin)
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
Completed
This phase I trial is studying the side effects and best dose of cetuximab when given together with cisplatin and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work i... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/29/2014
Locations: Georgia Regents University Medical Center, Augusta, Georgia
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus
Terminated
This study is designed pre-operative for patients with resectable, local-regional carcinoma of the esophagus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2014
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia
Conditions: Esophageal Diseases
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as dexrazoxane may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase III trial to study the effectiveness of three combination chemotherapy regimens plus dexrazoxane in treating patients who have newly diagnosed nonmetastatic osteosarcoma.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
08/04/2014
Locations: Emory University Hospital - Atlanta, Atlanta, Georgia
Conditions: Cardiac Toxicity, Sarcoma
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of etoposide plus radiation therapy followed by combination chemotherapy in treating children with newly diagnosed advanced medulloblastoma.
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
07/24/2014
Locations: Emory University Hospital - Atlanta, Atlanta, Georgia
Conditions: Brain Tumors, Central Nervous System Tumors
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and best dose of zoledronic acid when given together with combination chemotherapy in treating patients with newly diagnosed metastatic osteosarcoma.
Gender:
ALL
Ages:
40 years and below
Trial Updated:
06/04/2014
Locations: AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia
Conditions: Sarcoma